公开(公告)号：WO2006081007A2

公开(公告)日：2006-08-03

申请号：PCT/US2005/045833

申请日：2005-12-16

Applicant: WAKE FOREST UNIVERSITY HEALTH SCIENCES ,  MIZEL, Steven B.

Inventor： MIZEL, Steven B.

IPC: A61K39/02

CPC classification number: A61K39/0011 ,  A61K39/0291 ,  A61K2039/543 ,  A61K2039/55594 ,  A61K2039/575 ,  A61K2039/6068 ,  C07K2319/00 ,  Y02A50/407 ,  Y10S530/806 ,  Y10S530/825 ,  A61K2300/00 ,  A61K39/025

Abstract: The invention provides a fusion protein comprising a flagellin adjuvant and a tumor antigen. Also provided are compositions comprising a flagellin adjuvant and a tumor antigen. The invention further provides pharmaceutical formulations and methods for inducing an immune response against a tumor antigen and methods of treating a tumor in a subject.

Abstract translation: 本发明提供了包含鞭毛蛋白佐剂和肿瘤抗原的融合蛋白。 还提供了包含鞭毛蛋白佐剂和肿瘤抗原的组合物。 本发明还提供了用于诱导针对肿瘤抗原的免疫应答的药物制剂和方法以及治疗受试者的肿瘤的方法。

公开(公告)号：WO2003065973A2

公开(公告)日：2003-08-14

申请号：PCT/US2002/034769

申请日：2002-10-28

Applicant: ID BIOMEDICAL CORPORATION OF WASHINGTON ,  UNIVERSITY OF TENNESSEE RESEARCH CORPORATION ,  REDDISH, Mark, A. ,  HU, Mary, Chaohong ,  WALLS, Michael, A. ,  DALE, James, B.

Inventor： REDDISH, Mark, A. ,  HU, Mary, Chaohong ,  WALLS, Michael, A. ,  DALE, James, B.

IPC: A61K

CPC classification number: C12N15/70 ,  A61K39/00 ,  A61K2039/505 ,  C07K14/315 ,  C07K2319/00 ,  Y10S530/806 ,  Y10S530/825

Abstract: Compositions and methods for making and using therapeutic formulations of multivalent hybrid polypeptides comprising immunogenic peptides of M proteins from various different serotypes of group A streptococci and antibodies thereto are provided. Also provided are nucleic acids encoding such hybrid polypeptides. The hybrid polypeptide formulations may be used, for example, in methods for treating or preventing a microbial infection and eliciting a protective immune response having broadly protective opsonic antibodies in the absence of tissue cross-reactive antibodies.

Abstract translation: 制备和使用多价杂交多肽的治疗制剂的组合物和方法，其包含来自各种不同血清型A组链球菌及其抗体的M蛋白的免疫原性肽。 还提供了编码这种杂合多肽的核酸。 杂交多肽制剂可用于例如在不存在组织交叉反应性抗体的情况下用于治疗或预防微生物感染和引发具有广泛保护性opsonic抗体的保护性免疫应答的方法。

公开(公告)号：WO00062066A1

公开(公告)日：2000-10-19

申请号：PCT/JP2000/002245

申请日：2000-04-06

IPC: G01N33/564

CPC classification number: G01N33/564 ,  G01N2800/24 ,  Y10S435/975 ,  Y10S436/811 ,  Y10S530/806 ,  Y10S530/845

Abstract: A method for judging an autoimmune disease characterized by detecting the existence of anti-Reg protein autoantibody in a specimen; and a method for judging insulin dependent or noninsulin-dependent diabetes. A method for detecting anti-Reg protein autoantibody characterized by bringing a specimen into contact with an antigen component and detecting the formation of an immune complex. Diagnostics for autoimmune diseases which contain an antigen component capable of binding specifically to anti-Reg protein autoantibody; and diagnostics for insulin-dependent or noninsulin-dependent diabetes.

Abstract translation: 一种自身免疫性疾病的检测方法，其特征在于检测样品中抗-RF蛋白自身抗体的存在; 以及用于判断胰岛素依赖型或非胰岛素依赖性糖尿病的方法。 用于检测抗Reg蛋白自身抗体的方法，其特征在于使样品与抗原成分接触并检测免疫复合物的形成。 自身免疫性疾病的诊断，其含有能够特异性结合抗Reg蛋白自身抗体的抗原成分; 和胰岛素依赖型或非胰岛素依赖型糖尿病的诊断。

公开(公告)号：WO0005250A9

公开(公告)日：2000-10-12

申请号：PCT/US9916747

申请日：1999-07-23

Applicant: YEDA RES & DEV ,  HARVARD COLLEGE ,  AHARONI RINA ,  TEITELBAUM DVORA ,  ARNON RUTH ,  SELA MICHAEL ,  FRIDKIS HARELI MASHA ,  STROMINGER JACK L

Inventor： AHARONI RINA ,  TEITELBAUM DVORA ,  ARNON RUTH ,  SELA MICHAEL ,  FRIDKIS-HARELI MASHA ,  STROMINGER JACK L

IPC: A61K38/00 ,  A61K38/16 ,  A61K39/00 ,  A61L27/22 ,  C07K5/11 ,  C07K7/06 ,  C07K7/08 ,  C07K14/00 ,  C07K7/00

CPC classification number: G01N33/6842 ,  A61K38/16 ,  A61K39/0008 ,  A61L27/22 ,  A61L27/227 ,  C07K5/1019 ,  C07K7/06 ,  C07K7/08 ,  C07K14/001 ,  Y10S424/81 ,  Y10S530/806

Abstract: The present invention is directed to polypeptides and peptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid, at least one of the three amino acids is a charged amino acid and at least one amino acid is an aliphatic amino acid. In a preferred embodiment the polypeptide contains three or four of the following amino acids: tyrosine, alanine, glutamic acid or lysine. According to the present invention, the present polypeptides bind to antigen presenting cells, purified human lymphocyte antigens (HLA) and/or Copolymer 1-specific T cells. Morever, according to the present invention, these polypeptides can be formulated into pharmaceutical compositions for treating autoimmune disease. The present invention further contemplates methods of treating an autoimmune disease in a mammal by administering a pharmaceutically effective amount of any one of the present polypeptides or peptides to the mammal.

Abstract translation: 本发明涉及含有至少三个随机连接成线性阵列的氨基酸的多肽和肽; 其中三种氨基酸中的至少一种是芳族氨基酸，三种氨基酸中的至少一种是带电荷的氨基酸，并且至少一种氨基酸是脂族氨基酸。 在优选的实施方案中，多肽含有三个或四个以下氨基酸：酪氨酸，丙氨酸，谷氨酸或赖氨酸。 根据本发明，本发明多肽结合抗原呈递细胞，纯化的人淋巴细胞抗原（HLA）和/或共聚物1特异性T细胞。 此外，根据本发明，可将这些多肽配制成用于治疗自身免疫性疾病的药物组合物。 本发明进一步考虑了通过给予哺乳动物药学有效量的任何一种本发明的多肽或肽来治疗哺乳动物的自身免疫性疾病的方法。

公开(公告)号：WO99057142A3

公开(公告)日：2000-02-03

申请号：PCT/CA1999/000366

申请日：1999-05-06

IPC: C12P21/02 ,  A61K39/104 ,  A61K39/385 ,  A61P31/04 ,  C07K14/21

CPC classification number: A61K39/104 ,  A61K2039/505 ,  A61K2039/6037 ,  A61K2039/6081 ,  C07K14/21 ,  C07K2317/21 ,  Y10S530/806 ,  Y10S530/807 ,  Y10S530/825

Abstract: A C-terminal pilin peptide vaccine for immunizing or treating a patient for infection by a Pseudomonas aeruginosa (PA) infection is disclosed. The peptide comprises the peptide identified as SEQ ID NOS: 3-6; and a carrier protein conjugated to the peptide. Also disclosed is a pilin peptide C-terminal PA pilin peptide having the amino acid sequence identified as SEQ ID NO: 3, and analogs thereof having one of residues T, K, or A at position 130, D, T, or N at position 132, Q, A, or V at position 133, E, P, N, or A at position 135, Q, M, or K at position 136, and I, T, L, or R at position 138, excluding SEQ ID NOS: 1, 2, 9, 10, and 11, and the ability to cross-react with antibodies against the corresponding C-terminal peptides from PA stains PAK and PAO.

Abstract translation: 公开了用于免疫或治疗患者感染铜绿假单胞菌（PA）感染的C末端蛋白肽疫苗。 肽包含鉴定为SEQ ID NO：3-6的肽; 和与肽结合的载体蛋白。 还公开了具有鉴定为SEQ ID NO：3的氨基酸序列的pilin肽C-末端肽肽蛋白肽，其类似物在位置130，D，T或N的位置上具有残基T，K或A之一的位置 132，Q，A或V在位置136处的位置135，Q，M或K的位置133，E，P，N或A，以及138位的I，T，L或R，不包括SEQ ID NOS：1,2,9,10和11，以及与来自PA染色剂PAK和PAO的相应C末端肽的抗体交叉反应的能力。

公开(公告)号：WO9957142A2

公开(公告)日：1999-11-11

申请号：PCT/CA9900366

申请日：1999-05-06

Applicant: UNIV ALBERTA

Inventor： HODGES ROBERT S ,  IRVIN RANDALL T ,  CACHIA PAUL J

IPC: C12P21/02 ,  A61K39/104 ,  A61K39/385 ,  A61P31/04 ,  C07K14/21

CPC classification number: A61K39/104 ,  A61K2039/505 ,  A61K2039/6037 ,  A61K2039/6081 ,  C07K14/21 ,  C07K2317/21 ,  Y10S530/806 ,  Y10S530/807 ,  Y10S530/825

Abstract: A C-terminal pilin peptide vaccine for immunizing or treating a patient for infection by a Pseudomonas aeruginosa (PA) infection is disclosed. The peptide comprises the peptide identified as SEQ ID NOS: 3-6; and a carrier protein conjugated to the peptide. Also disclosed is a pilin peptide C-terminal PA pilin peptide having the amino acid sequence identified as SEQ ID NO: 3, and analogs thereof having one of residues T, K, or A at position 130, D, T, or N at position 132, Q, A, or V at position 133, E, P, N, or A at position 135, Q, M, or K at position 136, and I, T, L, or R at position 138, excluding SEQ ID NOS: 1, 2, 9, 10, and 11, and the ability to cross-react with antibodies against the corresponding C-terminal peptides from PA stains PAK and PAO.

Abstract translation: 公开了用于免疫或治疗患者感染铜绿假单胞菌（PA）感染的C末端蛋白肽疫苗。 肽包含鉴定为SEQ ID NO：3-6的肽; 和与肽结合的载体蛋白。 还公开了具有鉴定为SEQ ID NO：3的氨基酸序列的pilin肽C-末端肽肽素，其类似物在位置130，D，T或N位置上具有残基T，K或A之一的位置 132位的Q，A或V位于第136位的第135位，第13位，第13位，第13位，第13位，第13位，第13位，第13位，第13位，第13位，第13位， NOS：1,2,9,10和11，以及与来自PA染色剂PAK和PAO的相应C末端肽的抗体交叉反应的能力。

公开(公告)号：WO99038978A1

公开(公告)日：1999-08-05

申请号：PCT/US1999/002031

申请日：1999-01-29

IPC: A01H5/00 ,  A01K67/027 ,  A61K38/00 ,  A61K39/35 ,  C07K14/37 ,  C07K14/415 ,  C07K14/435 ,  C07K14/47 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/00 ,  C12N15/09 ,  C12N15/29

CPC classification number: C07K14/415 ,  A01K2217/05 ,  A61K38/00 ,  Y10S530/806 ,  Y10S530/868

Abstract: It has been determined that allergens, which are characterized by both humoral (IgE) and cellular (T cell) binding sites, can be modified to be less allergenic by modifying the IgE binding sites. The IgE binding sites can be converted to non-IgE binding sites by masking the site with a compound that prevents IgE binding or by altering as little as a single amino acid within the protein, most typically a hydrophobic residue towards the center of the IgE-binding epitope, to eliminate IgE binding. The method allows the protein to be altered as minimally as possible, other than within the IgE-binding sites, while retaining the ability of the protein to activate T cells, and, in some embodiments by not significantly altering or decreasing IgG binding capacity. The examples use peanut allergens to demonstrate alteration of IgE binding sites. The critical amino acids within each of the IgE binding epitopes of the peanut protein that are important to immunoglobulin binding have been determined. Substitution of even a single amino acid within each of the epitopes led to loss of IgE binding. Although the epitopes shared no common amino acid sequence motif, the hydrophobic residues located in the center of the epitope appeared to be most critical to IgE binding.

Abstract translation: 已经确定，通过改变IgE结合位点，可以将以体液（IgE）和细胞（T细胞）结合位点为特征的过敏原修饰为较不敏感。 通过用防止IgE结合的化合物掩蔽位点或通过改变蛋白质内的单个氨基酸，最常见的是向IgE-中心的疏水残基，将IgE结合位点转化为非IgE结合位点， 结合表位，以消除IgE结合。 该方法允许尽可能最小化蛋白质，除了在IgE结合位点之内，同时保持蛋白质激活T细胞的能力，并且在一些实施方案中，不显着改变或降低IgG结合能力。 实施例使用花生过敏原来证明IgE结合位点的改变。 确定了对免疫球蛋白结合重要的花生蛋白的每个IgE结合表位内的关键氨基酸。 每个表位中甚至单个氨基酸的取代导致IgE结合的丧失。 尽管表位不具有共同的氨基酸序列基序，但位于该表位中心的疏水性残基似乎对IgE结合最为关键。

公开(公告)号：WO98034642A1

公开(公告)日：1998-08-13

申请号：PCT/US1998/002194

申请日：1998-02-03

IPC: A61K38/00 ,  A61K35/26 ,  A61K38/21 ,  A61K39/00 ,  A61K39/002 ,  A61K39/02 ,  A61K39/12 ,  A61P31/00 ,  A61P35/00 ,  A61P37/04 ,  A61P43/00 ,  C12N5/08 ,  A61K39/385 ,  A61K39/39 ,  C07K1/10

CPC classification number: A61K39/0011 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61K2039/6043 ,  A61K2039/622 ,  Y02A50/466 ,  Y10S530/806 ,  Y10S530/807 ,  A61K2300/00

Abstract: The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule in combination with administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. "Antigenic molecule" as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e.), with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex when administered intradermally are in the range of 0.1 to 9.0 micrograms for complexes comprising hsp70, 5 to 49 micrograms for hsp90, and 0.1 to 9.0 micrograms for gp96. In another embodiment, the effective amounts of the complex when administered subcutaneously are in the range of 10 to 600 micrograms for complexes comprising hsp70, 50 to 5000 micrograms for hsp90, and 10 to 600 micrograms for gp96.

Abstract translation: 本发明涉及引发免疫应答和预防和治疗原发性和转移性肿瘤性疾病和传染病的方法和组合物。 本发明的方法包括施用包含有效量的复合物的组合物，其中复合物基本上由非共价结合于抗原分子的热休克蛋白（hsp）组合施用，与施用非共价hsps复合物致敏的抗原呈递细胞组合 与抗原分子结合。 本文所用的“抗原性分子”是指hsps与体内内源性相关的肽以及hsps在体内不络合的外源性抗原/免疫原（即）或其抗原性/免疫原性片段及其衍生物。 在优选的实施方案中，复合物是个体自体的。 在一个具体实施方案中，当皮内给药时复合物的有效量对于包含hsp70,5-49微克对于hsp90的复合物和对于gp96为0.1至9.0微克的复合物为0.1至9.0微克。 在另一个实施方案中，当皮下投与时，复合物的有效量对于包含hsp70,50-6000微克对于hsp90的复合物和对于gp96为10至600微克的复合物为10至600微克。

公开(公告)号：WO1997011180A1

公开(公告)日：1997-03-27

申请号：PCT/US1996015185

申请日：1996-09-20

Applicant: CORIXA CORPORATION

Inventor： CORIXA CORPORATION ,  REED, Steven, G. ,  CAMPOS-NETO, Antonio ,  WEBB, John, R. ,  DILLON, Davin, C. ,  SKEIKY, Yasir, A., W.

IPC: C12N15/30

CPC classification number: C07K14/44 ,  A61K38/00 ,  A61K39/00 ,  Y02A50/41 ,  Y10S530/806

Abstract: Compositions and methods for preventing, treating and detecting leishmaniasis and stimulating immune responses in patients are disclosed. The compounds provided include polypeptides that contain at least an immunogenic portion of one or more Leishmania antigens, or a variant thereof. Vaccines and pharmaceutical compositions comprising such polypeptides are also provided and may be used, for example, for the prevention and therapy of leishmaniasis, as well as for the detection of Leishmania infection.

Abstract translation: 公开了用于预防，治疗和检测利什曼病并刺激患者免疫应答的组合物和方法。 提供的化合物包括含有至少一种或多种利什曼原虫抗原的免疫原性部分或其变体的多肽。 还提供包含这些多肽的疫苗和药物组合物，并且可以用于例如预防和治疗利什曼病以及用于检测利什曼原虫感染。

公开(公告)号：WO1996040927A1

公开(公告)日：1996-12-19

申请号：PCT/US1996009158

申请日：1996-06-04

Applicant: AMBICO, INC.

Inventor： AMBICO, INC. ,  QUICK, Douglas, P. ,  WELTER, Mark, W. ,  WELTER, C., Joseph ,  WELTER, Lisa, M. ,  STEGER, Ann, M.

IPC: C12N15/30

CPC classification number: C07K14/44 ,  A61K38/00 ,  A61K39/00 ,  C07K16/20 ,  Y10S435/947 ,  Y10S530/806 ,  Y10S530/822

Abstract: Isospora suis is propagated using a swine testicular cell line which facilitates production of sporozoites and merozoites, either or both of which can be used in a vaccine for swine. Neutralizing antibodies against sporozoites have been made, and DNA encoding a portion of an apparent sporozoite attachment protein or a derivative or mutant thereof may likewise be used in a vaccine. Nursing piglets can be passively protected from infection by Isospora suis by inoculating the dam and permitting the piglets to nurse from the dam.

Abstract translation: 使用猪睾丸细胞系繁殖异孢子体，这促进子孢子和裂殖子的生产，其中一种或两种可以用于猪的疫苗。 已经制备了针对子孢子的中和抗体，编码一部分表观子孢子附着蛋白或其衍生物或突变体的DNA同样可用于疫苗中。 通过接种大坝并允许仔猪从大坝中护理，可以将哺育仔猪被动地保护免于异源孢子虫感染。